EUCTR2017-001820-22-DE进行中（未招募）1 期
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT) - CONSTANT
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 3,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Any gender.
- •2. Age 18-45 years.
- •3. Healthy, as determined by a physical examination and values of laboratory tests.
- •4. If female a) either not of childbearing potential, defined as postmenopausal (12 months with no menses without an alternative medical cause) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy),
- •b) is of childbearing potential and must agree to use an adequate birth control method 4 weeks prior to first vaccination and until the end of her participation in the study (effective birth control includes: 1) hormonal (implant, oral, vaginal, transdermal) contraceptives;
- •2) diaphragm with spermicide, condom (with or without spermicide); 3) intra-uterine devices; and 4) vasectomy of male partner; 5) abstinence from penile-vaginal intercourse (if the preferred and usual lifestyle of the subject)).
- •5. Able and willing to give informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3200
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous vaccination with any HBV vaccine (licensed or experimental).
- •2. Treatment by immunosuppressant within 30 days of enrollment including but not limited to
- •corticosteroids at a dose that is higher than an oral or injected physiological dose, or > 20 mg /day
- •prednisolone equivalent (Inhaled and topical steroids are allowed).
- •3. History of immunological function impairment, including but not limited to:
- •a) autoimmune diseases (e.g. multiple sclerosis, type 1 diabetes, myasthenia gravis, Crohn disease and other inflammatory bowel diseases, celiac disease, systemic lupus erythematosus, scleroderma, including diffuse systemic form and CREST syndrome, systemic sclerosis, dermatomyositis polymyositis, rheumatoid arthritis, juvenile idiopathic arthritis, autoimmune thyroiditis - including Hashimoto thyroiditis, Grave's or Basedow’s disease, immune thrombocytopenic purpura, autoimmune hemolytic anemia, autoimmune hepatitis, psoriasis, vitiligo, vasculitis, Guillain-Barré syndrome, Addison’s Disease, Bell’s Palsy and Alopecia Areata);
- •b) secondary immunodeficiency disorders (e.g. Acquired Immunodeficiency Syndrome caused by Human Immunodeficiency Virus infection (HIV/AIDS), solid organ transplant, splenectomy);
- •c) primary immunodeficiency disorders (e.g. common variable immune deficiency (CVID), Defective phagocytic cell function and neutropenia syndromes, complement deficiency).
- •4.Pregnancy or breastfeeding.
- •5. Immunization with attenuated vaccines (e.g. MMR) within 4 weeks prior to enrollment.
- •6. Immunization with inactivated vaccines (e.g. influenza) within 2 weeks prior to enrolment.
- •7. Has received blood products or immunoglobulin within 90 days prior to study entry or likely to require blood products during the study period.
- •8. Subject in another clinical trial with an investigational drug or a biologic within 30 days of enrollment.
- •9. Has received granulocyte-macrophage stimulating factor (G/GM-CSF) or erythropoietin (EPO) within 30 days of enrollment or likely to require GM-CSF erythropoietin during the study period.
- •10. Any history of cancer requiring chemotherapy or radiation within 5 years of randomization or current disease. Subject with an history of low risk basal cell carcinoma will be accepted (low risk being defined by the following:
- •1) location on the trunk of the body, arms, legs, cheeks, forehead, temples, scalp, neck or chin and
- •2) less than 2 cm, and
- •3) nodular or superficial, and
- •4) primary cancer that has not come back after treatment and
- •5) edge of the cancerous area is clear and smooth and
- •6) not located in or around nerves).
- •11. Any skin abnormality or tattoo that would limit post-vaccination injection site assessment.
- •12. History of allergic reactions or anaphylactic reaction to any vaccine component or allergy to latex.
- •13. Unwilling, or unable in the opinion of the investigator, to comply with study requirements, including the use of an adequate birth control method.
- •14. Immediate family members of study center staff (parents, sibling, children).
研究者
相似试验
进行中（未招募）
1 期
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in AdultsEUCTR2017-001820-22-GBVBI Vaccines INC.3,200
进行中（未招募）
1 期
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in AdultsHepatitis B VaccinationMedDRA version: 20.0 Level: LLT Classification code 10054181 Term: Hepatitis B immunization System Organ Class: 100000004865EUCTR2017-001820-22-BEVBI Vaccines INC.3,200
进行中（未招募）
1 期
A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in AdultsHepatitis B VaccinationMedDRA version: 21.1 Level: LLT Classification code 10054181 Term: Hepatitis B immunization System Organ Class: 100000004865EUCTR2017-001820-22-FIVBI Vaccines INC.3,200
已完成
4 期
A randomized double-blind controlled trial to assess the benefits of olanzapine and amisulpride combination treatment in acutely illschizophrenia patients.-COMBINEF20F25Schizoaffective disordersSchizophreniaDRKS00003603niversitätsklinikum Düsseldorf328
已完成
不适用
Safety and efficacy of Ayurvedic Capsule in mild to moderate COVID-19 infection.CTRI/2020/07/026570AMAI Charitable Trust Pune72